Location History:
- Kobe, JA (1977)
- Kobe, JP (1982 - 1993)
- Hyogo, JP (2004)
Company Filing History:
4 out of 1,001 
1 out of 25 Years Active: 1977-2004
Title: Ken Inouye: Innovator in Monoclonal Antibody Development
Introduction
Ken Inouye is a notable inventor based in Hyogo, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 5 patents to his name, Inouye's work has had a profound impact on medical diagnostics.
Latest Patents
One of Inouye's latest patents is for a monoclonal antibody recognizing the C-terminus of human brain natriuretic peptide (hBNP). This invention involves cultivating a hybridoma in a medium or the abdominal cavity of a mouse to recover the monoclonal antibody. The resulting immunoassay for hBNP is highly sensitive, with a minimum detection limit of 1 pg/ml, allowing for direct measurement of hBNP levels in blood plasma. This innovation is particularly useful for diagnosing conditions such as hypertension and various heart and kidney diseases.
Another significant patent by Inouye is a radioactive iodine compound for labeling antibodies. This compound enables the introduction of a radioactive isotope, such as .sup.125 I, into an antibody molecule without compromising its activity. This advancement enhances the sensitivity of immunoradiometric assays, making it a valuable tool in medical diagnostics.
Career Highlights
Throughout his career, Ken Inouye has worked with prominent companies, including Shionogi Company Limited and Shionogi Seiyaku Kabushiki Kaisha. His experience in these organizations has contributed to his expertise in the field of biotechnology and patent development.
Collaborations
Inouye has collaborated with notable colleagues, including Masao Kono and Akira Yamauchi. These partnerships have fostered innovation and advancement in their respective fields.
Conclusion
Ken Inouye's contributions to the development of monoclonal antibodies and radioactive compounds have significantly advanced medical diagnostics. His innovative work continues to influence the biotechnology industry and improve patient care.